These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 482695

  • 21. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P.
    Eur J Pharmacol; 2010 Jun 10; 635(1-3):109-16. PubMed ID: 20303948
    [Abstract] [Full Text] [Related]

  • 22. [Regulatory influence of free fatty acids on nocturnal secretion of growth hormone].
    Lucke C, Glick SM.
    Verh Dtsch Ges Inn Med; 1972 Jun 10; 78():1318-20. PubMed ID: 4665532
    [No Abstract] [Full Text] [Related]

  • 23. [Inhibition of GH secretion by nonesterified fatty acids when stimulated by glucagon].
    Cabezas-Cerrato J, Villanueva Arangúren L, Casanueva F, Vila T, Fernández-Cruz A.
    Rev Clin Esp; 1975 Jul 31; 138(2):107-11. PubMed ID: 1178955
    [No Abstract] [Full Text] [Related]

  • 24. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
    Minsker DH, Stokes AL.
    Experientia; 1974 Sep 15; 30(9):1051-3. PubMed ID: 4412113
    [No Abstract] [Full Text] [Related]

  • 25. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE.
    Eur Neurol; 1987 Sep 15; 27 Suppl 1():9-20. PubMed ID: 3123242
    [Abstract] [Full Text] [Related]

  • 26. Skeletal changes induced by dopa decarboxylase inhibitor in rats.
    Tanaka C, Tanaka S, Itokawa Y, Takaori S.
    Jpn J Pharmacol; 1973 Feb 15; 23(1):123-5. PubMed ID: 4541614
    [No Abstract] [Full Text] [Related]

  • 27. [Effect of L-dopa combined with benserazide on hemodynamics and motor activity in hypoxic rats].
    Boismare F, Le Poncin M, Belliard JP, Hacpille L.
    C R Seances Soc Biol Fil; 1975 Feb 15; 169(1):203-8. PubMed ID: 126730
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602).
    Bakke OM, Scheline RR.
    J Pharm Pharmacol; 1974 May 15; 26(5):377-9. PubMed ID: 4152920
    [No Abstract] [Full Text] [Related]

  • 29. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
    Shimamura M, Shimizu M, Yagami T, Funabashi T, Kimura F, Kuroiwa Y, Misu Y, Goshima Y.
    Neuropharmacology; 2006 Jun 15; 50(8):909-16. PubMed ID: 16504219
    [Abstract] [Full Text] [Related]

  • 30. [Effects of benserazide administration on prolactin secretion].
    Masturzo P, Murialdo G, Gallamini A, Nizzo MC, Magnani G.
    Boll Soc Ital Biol Sper; 1978 Feb 15; 54(3):274-8. PubMed ID: 687436
    [No Abstract] [Full Text] [Related]

  • 31. [Stimulation of growth hormone secretion by the anterior pituitary gland using L-DOPA compared to growth hormone secretion following argine, insulin and sleep].
    Lucke C, Höffken B, Morgner KD.
    Verh Dtsch Ges Inn Med; 1974 Feb 15; 80():1328-30. PubMed ID: 4454413
    [No Abstract] [Full Text] [Related]

  • 32. Possible mechanism of adverse reaction following levodopa plus benserazide treatment.
    Messiha FS.
    Br J Pharmacol; 1977 May 15; 60(1):55-7. PubMed ID: 884390
    [Abstract] [Full Text] [Related]

  • 33. The effect of dihydroergotoxine-ethanesulphonate (Redergam) on the basal and with 3-(3,4-dihydroxyphenyl)-L-alanine (L-DOPA) stimulated somatotrophic secretion of diabetic patients.
    Dobrew D, Zonew I, Milanow S.
    Ther Hung; 1977 May 15; 25(4):145-9. PubMed ID: 605413
    [No Abstract] [Full Text] [Related]

  • 34. Effects of 5-hydroxytryptamine, dopamine, and aromatic L-amino acids on growth hormone (GH)-releasing factor-stimulated GH release in rat anterior pituitaries.
    Lindström P, Ohlsson L.
    Endocrinology; 1987 Feb 15; 120(2):780-4. PubMed ID: 3100280
    [Abstract] [Full Text] [Related]

  • 35. Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor.
    Doller HJ, Connor JD, Lock DR, Sloviter RS, Dvorchik BH, Vesell ES.
    Drug Metab Dispos; 1978 Feb 15; 6(2):164-8. PubMed ID: 26532
    [Abstract] [Full Text] [Related]

  • 36. Pituitary hormone secretion after inhibition of L-aromatic amino acid decarboxylase activity in man.
    Delitala G, Devilla L, Pende A.
    Acta Endocrinol (Copenh); 1980 Dec 15; 95(4):438-43. PubMed ID: 7456974
    [Abstract] [Full Text] [Related]

  • 37. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P, Chiurulla C, Gambi D, Mennuni G, Pinto F.
    Acta Neurol Belg; 1975 Dec 15; 75(1):5-10. PubMed ID: 1202895
    [Abstract] [Full Text] [Related]

  • 38. Cardiovascular responses to acute hypoxia in dogs pretreated with benserazide and L-DOPA.
    Boismare F, Le Poncin M, Hacpille L.
    Eur J Pharmacol; 1976 Jul 15; 38(1):1-5. PubMed ID: 954818
    [Abstract] [Full Text] [Related]

  • 39. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS.
    Drugs; 1976 Jul 15; 11(5):329-77. PubMed ID: 782834
    [No Abstract] [Full Text] [Related]

  • 40. The action L-dopa on sexual behaviour of male rats.
    Da Prada M, Carruba M, Saner A, O'Brien A, Pletscher A.
    Brain Res; 1973 Jun 15; 55(2):383-9. PubMed ID: 4541349
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.